December 9, 2019 8:51am

Futures set for first loss in four sessions

News: Sangamo Therapeutics (SGMO) announced preliminary results from the first three (3) patients in a P1/2 study evaluating ST-400 ex-vivo gene-edited cell therapy in Beta Thalassemia. The patients experienced prompt hematopoietic reconstitution, and no clonal hematopoiesis. Beta thalassemia is a rare blood disorder caused by a mutation in the beta-globin gene that results in impaired production of red blood cells.

Pre-open indications:  BUY – SGMO; SELL: RENE.L, SAGE, GBT CRSP and QURE

Skim if you can trim, buy if it will fly and sell if compelled!

 

The 6 W’s: Who, what, where, when, why and what of it … so who has done what?

 

Dow futures are DOWN -0.10% (-28 points), S&P futures are DOWN -0.10% (-3 points) and NASDAQ futures are DOWN -0.15% (-13 points)

 

U.S. stock index futures were slightly lower on Monday as investors took a pause after three consecutive days of increases;

European stocks traded slightly lower while the pan-European Stoxx 600 slipped -0.1% lower;

Asia Pacific stocks edged higher as China’s exports declined in November for the fourth consecutive month, according to the country’s customs data.

 

Data Docket: none

 

Henry’omics:

Be ready after indexes rose to near-record highs late last week, boosted a U.S. jobs report that easily topped analyst expectations.

Investor focus turned back to the prospect of a limited trade agreement between the U.S. and China, with less than a week to go before Washington is set to impose even more tariffs on Chinese goods.

Beijing’s trade discussions with Washington have yet to yield a much-touted “phase one” agreement ahead of a key deadline for additional tariffs on Chinese exports to the U.S. on Dec. 15.

 

Good session to watch and wait while sitting on the sidelines!

 

Friday night’s post, “:tailwinds, headwinds and tailwinds again describes a situation that moves share pricing and momentum gets driven as volume grows and wanes.”

  • Last week in review: 3 positive and 2 negative closes;
  • Friday, the NASDAQ closed UP +85.83 points (+1%); the IBB closed up +1.17% while the XBI closed up +1.15%;
  • Friday’s range of the 29 upside was +0.07% (BOLD) to +11.66% (RENE.L) while the 9 downside ranged from -0.20% (BMRN) to -3.68% (AGTC); 
  • 7 out of the 29 upside had higher than the 3 month average volume;
  • 5 out of the 9 downside had higher than the 3 month average volume;

 

Review the content of Q4’s market:

  • December register 3 negative and 2 positive closes … so far
  • November registered 1 holiday, 12 positive and 8 negative close;
  • October registered 10 positive, 1 neutral and 14 negative closes;

 

Companies in my headlights – It’s your decision; I provide an idea and context:

SELL into strength versus BUY “some not many” on weakness

Pre-open indications:  BUY – SGMO; SELL: RENE.L, SAGE, GBT CRSP and QURE

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.